Supply Flibanserin Hydrochloride CAS 147359-76-0
Flibanserin Hydrochloride powder is used for hypoactive sexual desire disorder among women.
Those receiving flibanserin report a 0.5 increase compared to
placebo in the number of times they had “satisfying sexual events”.In
those on flibanserin it rose from 2.8 to 4.5 times a month while women
receiving placebo reported also an increase of “satisfying sexual
events” from 2.7 to 3.7 times a month.The onset of the flibanserin
effect was seen from the first timepoint measured after 4 weeks of
treatment and maintained throughout the treatment period.
2.The effectiveness of flibanserin was evaluated in three phase 3 clinical trials.
Each of the three trials had two co-primary endpoints, one for
satisfying sexual events (SSEs) and the other for sexual desire. Each of
the 3 trials also had a secondary endpoint that measured distress
related to sexual desire. All three trials showed that flibanserin
produced an increase in the number of SSEs and reduced distress related
to sexual desire. The first two trials used an electronic diary to
measure sexual desire, and did not find an increase. These two trials
also measured sexual desire using the Female Sexual Function index
(FSFI) as a secondary endpoint, and an increase was observed using this
latter measure. The FSFI was used as the co-primary endpoint for sexual
desire in the third trial, and again showed a statistically significant
increase.
Flibanserin is used for hypoactive sexual desire disorder among
women. Those receiving flibanserin report a 0.5 increase compared to
placebo in the number of times they had “satisfying sexual events”.In
those on flibanserin it rose from 2.8 to 4.5 times a month while women
receiving placebo reported also an increase of “satisfying sexual
events” from 2.7 to 3.7 times a month.The onset of the flibanserin
effect was seen from the first timepoint measured after 4 weeks of
treatment and maintained throughout the treatment period.
The effectiveness of flibanserin was evaluated in three phase 3
clinical trials. Each of the three trials had two co-primary endpoints,
one for satisfying sexual events (SSEs) and the other for sexual desire.
Each of the 3 trials also had a secondary endpoint that measured
distress related to sexual desire. All three trials showed that
flibanserin produced an increase in the number of SSEs and reduced
distress related to sexual desire. The first two trials used an
electronic diary to measure sexual desire, and did not find an increase.
These two trials also measured sexual desire using the Female Sexual
Function index (FSFI) as a secondary endpoint, and an increase was
observed using this latter measure. The FSFI was used as the co-primary
endpoint for sexual desire in the third trial, and again showed a
statistically significant increase.
